Cannaponics, a medicinal cannabis manufacturer based in Western Australia, is preparing for a public listing on the Australian Securities Exchange (ASX) later this year. The company aims to capitalize on the burgeoning legal cannabis market, expected to exceed USD 102 billion (approximately AUD 152.4 billion) by 2030. With plans to produce 15,000 tonnes of medicinal cannabis annually at its 165-acre facility in Collie, the company is set for its first harvest in March or April 2024.
Rod Zakostelsky, the CEO of Cannaponics, has been proactive in positioning the company for future growth. He has diversified the company’s revenue streams, which includes the recent acquisition of the Club Hotel Collie for AUD 550,000. This strategic move was partly motivated by concerns regarding the local housing crisis and its potential impact on attracting and retaining staff.
The Club Hotel Collie, which features 21 rooms, three bars, and a bottle shop, has reportedly helped the company nearly double its revenue to AUD 6 million since its purchase. Zakostelsky plans to enhance this revenue further by constructing an additional 48 rooms on-site, projecting annual revenue to reach AUD 14 million.
Market Insights and Future Plans
Zakostelsky emphasized the importance of diversification in navigating potential challenges within the cannabis industry. He predicts significant consolidation in the sector over the next 12 to 36 months. Despite these challenges, several industry analyses indicate a positive outlook, forecasting substantial growth in the global legal cannabis market.
“We’re one of only half a dozen growers here in the country at the scale that we have, so for us it’s exciting to be part of that,” Zakostelsky stated, highlighting Cannaponics’ competitive position in the market.
As Cannaponics prepares for its initial public offering, it has enlisted the stockbroking firm Morgans to serve as the lead manager and advisor. This development comes shortly after a significant policy shift in the United States, where President Donald Trump signed an executive order reclassifying cannabis from a Schedule I drug to a Schedule III drug. This change aligns cannabis with certain prescription painkillers, potentially easing access in the U.S. market.
As Cannaponics moves forward, its focus on innovation and expansion in a growing market could position the company for long-term success in the evolving landscape of legal cannabis.
